| Sanofi-Aventis (Suisse) SA - Vaxigrip, suspension injectable | | 70051 | | 03 | | Vaxigrip | | suspension injectable | | J07BB02 | | Influenza, gereinigtes Antigen | | 13.08.2026 | | |
| | Composition | | haemagglutininum influenzae A (H1N1) (Virus souche A/Missouri/11/2025 (H1N1)pdm09-like: reassortant virus IVR-278 derived from A/Switzerland/6849/2025) 15 µg, haemagglutininum influenzae A (H3N2) (Virus souche A/Darwin/1454/2025 (H3N2)-like: reassortant virus SAN-049A derived from A/Michigan/105/2025) 15 µg, haemagglutininum influenzae B (Virus souche B/Tokyo/EIS13-175/2025-like: B/Tokyo/EIS13-175/2025, wilde type (Victoria lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.72 mg, kalium 0.08 mg, residui: formaldehydum, octoxinolum-9, ovalbuminum, neomycinum. | | Packungsbestandteile | | | | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 005 | | | | B | | Oui | | 006 | 10 | | | B | | Oui |
|
|
